It is worth noting that recent clinical trials (such as STEP-HFpEF) suggest that despite a reduction in lean body mass, patients physical functioning (such as exercise endurance) may still significantly improve, indicating that we need to reassess the clinical balance between muscle mass decline and functional benefits.In clinical practice, the potential risks of GLP-1RAs cannot be ignored, especially in the elderly and those already suffering from sarcopenia
Retrieved from Dobranowska, K., Pliska, S., & Dobosz, A
Phase 3 TRIUMPH trial data has pushed that figure even higher, with topline results showing approximately 2830% mean weight loss at 80104 weeks
The results showed that liraglutide reduced visceral fat while relatively increasing subcutaneous fat
FDA [1] has approved semaglutide under three different brand names, and each one is used a little differently: Ozempic: This is an injection that helps manage blood sugar in type 2 diabetes
Retatrutide is the most studied of the triple agonists, with the strongest public efficacy data, which is why it dominates the conversation